observation. The platelet decrease was closely related to the number of cells injected. Intra-arterial tumour cell injections required a considerably higher tumour cell count to produce a comparable thrombocytopenia. Non-viable tumour cells and tumour cell fragments induced a similar decrease of circulating platelets. Neither viable tumour cells nor tumour cell fragments aggregated rat platelets in vitro. The presence of fibrin monomers in tumour cell injected animals suggested intravascular fibrin deposition; the plasma fibrinogen level, however, did not decrease significantly. Isotope studies using 51Cr labelled platelets revealed a rapid disappearance of the platelets from the circulation and their trapping in' the lung-the primary site of tumour cell lodgement. Dipyridamole and ancrod pretreatment did not influence the decrease of platelets and their accumulation in the lung after tumour cell injection. In contrast, heparin completely prevented the thrombocytopenia and the platelet trapping in the lung. From the present experiments it is concluded that embolic tumour cells lead to early endothelial damage, resulting in local thrombin formation with subsequent irreversible platelet aggregation.
EXPERIMENTAL evidence has accumulated indicating that the activation of the blood clotting mechanism at the site of tumour cell lodgement is a part of the pathology of metastatic tumour growth and in vivo observations in the rabbit ear chamber demonstrated clot formation around embolic tumour cells (Wood, Holyoke and Yardley, 1961) . Inhibitors of blood coagulation or fibrinolytic agents were shown to reduce blood bone metastases in experimental conditions (Wood et al., 1961; Cliffton and Agostino, 1965; Agostino and Cliffton, 1965; Ryan, Ketcham and Wexler, 1968) . It has been concluded that fibrin formation around adherent tumour cells is an important step in the establishment of haematogenous metastases.
It was assumed that blood platelets are involved in tumour cell lodgement as well as participating in thrombus formation, and that they may represent an additional mediator of metastasis formation (Gasic, Gasic and Stewart, 1968) . The present investigations were designed to obtain further information about the behaviour of blood platelets after administration of experimental tumour cells into the blood stream. The Walker carcinosarcoma 256 of the rat was chosen for these experiments because the ultrastructure of its intravascular behaviour is fairly well investigated (Griffith and Salsbury, 1963; Jones, Wallace and Fraser, 1971; Warren and Vales, 1972 (Cliffton et al., 1971 The Walker carcinosarcoma 256, originated from a spontaneously grown mammary adenocarcinoma (Stewart et al., 1959) , was transferred to the ascitic form (Agostino and Clifton, 1968) (110-150 g ). The intramuscular transplantation of 5 x 106 tumour cells resulted in the animals' death 9-10 days later, at which time the solid tumour had a diameter of 3-4 cm. Six days after the intraperitoneal inoculation the ascites was harvested for the experiments. After washing and differential centrifugation at 4°C with buffered saline (pH 7 4) containing 5%0 dextrose, the tumour cell suspension was adjusted to the desired cell count with buffered saline-500 dextrose.
The viability of the tumour cell suspensions, or the suspensions of cell fragments, was assessed by intramuscular transplantation of 5 x 106 cells into healthy control animals.
Tumour cell fragments were prepared by triple freezing and thawing of a tumour cell suspension with a known cell count. Finally, the fragments were washed and resuspended in buffered saline to the original volume. The supernatant was kept and frozen for later platelet aggregation studies.
All injections were made during methoxyflurane (Penthrane, Abbott Laboratories Ltd.) anaesthesia into the lateral tail veins of the animals. In some instances tumour cell suspensions were injected into the thoracic aorta via a polyethylene cainula inserted into the femoral artery.
Blood samples were obtained under methoxyflurane anaesthesia by aortic puncture and the blood was allowed to flow directly into a polyethylene test tube containing 2 mg of EDTA. Serial platelet counts were performed from tail vein blood.
Platelet counts were made in duplicate (Brecher and Cronkite, 1950 ) and the plasma fibrinogen was estimated according to the method of Ratnoff and Menzie (1951) . The screening for fibrin monomers in plasma was performed with the protamine precipitation test (Sanfelippo, Stevens and Koenig, 1971) .
Platelet aggregation was measured in a platelet aggregation meter (Evans Electroselenium Ltd.) using rat platelet rich plasma and 3808% sodium citrate (1: 10) as anticoagulant. Aggregating substances were suspensions of freshly prepared collagen particles, fresh tumour cell suspensions, tumour cell fragments and tumour cell extracts. After addition of the test sample the decrease of light transmission was recorded.
Rat platelets from healthy donor animals were labelled with 51Cr as described by Dacie and Lewis (1968) . 0 5 ml of platelet rich plasma, containing approximately 9 x 105 labelled platelets per mm3 (corresponding to approximately 8 x 104 ct/min) was injected intraveously into 24 rats. Twenty-four hours later a tumour cell suspension (5 x 106 cells) was injected into 12 animals; 12 control animals received the same volume of buffered saline. Five minutes after the tumour cell or saline injections the animals were killed by rapid intraveous injection of 0-5 ml of Nembutal (Abbott Laboratories Ltd.). Blood was obtained by heart puncture before death. The right lung, parts of the liver, the spleen and one kidney were removed. After determination of the wet weight the radioactivity was measured in a conventional scintillation counter and converted to ct/min/g tissue.
Twenty-four hours before the injection of 5 x 106 tumour cells, 40 animals were injected with labelled platelets as described. The animals were divided into 5 groups and pretreated with intravenous injections of either heparin (Weddel Pharmaceuticals injected into the arterial side. A considerable increase in the tumour cell count is necessary to produce a comparable thrombocytopenia by intra-arterial injection (Table II) .
The organ distribution of 51Cr labelled platelets 5 minutes after the intravenous injection of 5 x 106 tumour cells is shown in Fig. 2 . The decrease of blood activity and the increase of lung activity in the tumour cell injected animals (n 12) is highly significant (P in both cases < 0.01) if compared with the control group (n 12). The platelet distribution in the liver, spleen and kidneys is identical in the 2 groups. Table III demonstrates of 5 x 106 tumour cells. The radioactivity in the lungs and the blood radioactivity had an inverse relationship. Saline, dipyridamole and ancrod pretreatment did not influence the accumulation of platelets in the lungs nor their disappearance from the blood. These groups are statistically not different from each other. Heparin prevented the decrease of blood activity and the increase in lung activity if compared with the other treated groups (P < 0 01). The blood activity in the various groups is closely related to the amount of circulating platelets, which is also demonstrated in Table III. The injection of 750 u/kg body weight of heparin into otherwise untreated animals (n _ 5) prolonged the whole blood clotting time from 2-5 (± 0.7) minutes to over 30 minutes; the platelet count was not altered by the heparin treatment. Ninety u/kg body weight of ancrod injected intravenously revealed the absence of clottable fibrinogen 30 minutes after the injection (n 5); the platelet count did not differ significantly from the initial values.
The plasma fibrinogen level was determined in 12 control and 12 tumour cell injected (5 x 106 cells) animals. The tumour cell injected animals were bled 15 minutes (n 6) and 30 minutes (n 6) after the injection. The mean value for the control animals was 255 mg/100 ml (± 40 mg/l00 ml) against a mean value in the tumour group of 230 mg/100 ml (± 45 mg/100 ml) at 15 minutes and 235 mg/100 ml (± 30 mg/100 ml) at 30 minutes. These dif- (Jones et al., 1971) . Since Gasic et al. (1968) reported that neuraminidase induced thrombocytopenia was associated with a significant reduction of experimental metastases in mice, some consideration has been directed towards a platelet-tumour cell interaction in the lodgement of haematogenous tumour cells (Gastpar, 1970; Kolenich, Mansour and Flynn, 1972; Gasic, Gasic and Murphy, 1972; Wood and Hilgard, 1972) . None of the experimental data available allow any conclusion concerning the mechanism of platelet involvement in early metastasis formation and it seemed desirable to elucidate this phenomenon.
The immediate drop in the number of circulating blood platelets following the intravenous injection of a tumour cell suspension obviously represents the haematological counterpart to the morphological finding of tumour cells associated with platelet clusters (Jones et al., 1971; Warren and Vales, 1972 In contrast to Warren's (1970) Pretreatment with dipyridamole in a dose which inhibits platelet aggregation (Cucuianu, Nichizawa and Mustard, 1971) was ineffective in preventing the tumour cell induced decrease of blood platelets. On the other hand, heparin completely inhibited the development of the thrombocytopenia. The lack of an increased platelet accumulation in the lungs of heparinized animals suggests that the formation of tumour cell associated platelet aggregates was inhibited by heparin, whereas dipyridamole was ineffective.
The presence of fibrin monomers indicated that, in spite of the unchanged plasma fibrinogen levels, intravascular fibrin formation accompanied the consumption of blood platelets. To study the behaviour of blood platelets in the absence of clottable fibrinogen, the animals were rendered afibrinogenaemic by the injection of ancrod (a fraction of the venom from the Malayan pit viper Akistrodon rhodostoma). Ancrod induces a state of hypofibrinogenaemia in various laboratory animals by formation of intravascular microclots which are rapidly removed from the circulation (Ashford, Ross and Southgate, 1968) . The number and function of circulating platelets are not affected by this treatment (Davey and Luischer, 1965) . The identical pattern of the platelet decrease and their increased accumulation in the lung after tumour cell injection in afibrinogenaemic animals indicate that the formation of thrombin at the site of tumour cell lodgement is the crucial event. Thrombin induces intravascular platelet aggregation and the platelet release reaction earlier and at lower concentrations than it induces fibrin formation (Mustard and Packham, 1970 al., 1972) . Heparin of course, interferes with the formation of thrombin and therefore probably inhibited the development of the thrombocytopenia in this experimental model.
The degree of the thrombocytopenia in the present experiments was highly dependent upon the route of injection of the tumour cells, which indicates that local factors rather than tumour cell related factors are involved in the generation of thrombin. Ashford and Frieman (1968) demonstrated that minimal endothelial trauma results in platelet clusters associated with the surface of the endothelium. If the endogenous fibrinolytic response was inhibited by epsilon-amino caproic acid pretreatment these platelets were intimately associated with fibrin. In view of previous light microscopy studies (Wood, 1958) it seems justifiable to assume that tumour cells induce such minimal endothelial lesions at the site of their arrest in the blood vessel. Breaks in the plasma membrane, with exposure of cytoplasmic contents of the endothelial cells to the plasma, may lead to local activation of the clotting mechanism with formation of thrombin. Johnson et al. (1965) concluded from their ultrastructural studies that thrombin must form very early after endothelial damage and that it diffuses rapidly around the blood cells in that area. The fact that non-viable tumour cells and tumour cell membranes behave identically with viable tumour 434 cells in regard to their effect upon circulating platelets further suggests that the interaction of the tumour cell membrane with the vascular endothelium and its subsequent damage is the primary event.
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